A Phase 4 interventional study of Carbidopa/levodopa/entacapone in Parkinson's Disease With End of Dose Wearing Off, sponsored by Novartis Pharmaceuticals. Completed at 42 sites in 2 countries. Open to participants aged 30 Years to 85 Years. Per ClinicalTrials.gov, last updated 2017-03-30.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing carbidopa in Parkinson Disease — 1 open to participants now, 1 under way, none of them phase 3. Carbidopa · Parkinson Disease.
Among the 24 studies testing carbidopa in Parkinson Disease, this one is the 3rd largest by enrollment, is one of 3 that started in 2005, is one of 9 in phase 4, and was the 2nd registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.
Browse Parkinson Disease studies →1 of the 24 studies testing carbidopa in Parkinson Disease is open now, in 1 country. Recruiting first, the newest first:
Second Affiliated Hospital of Soochow University · Sites in China
Ages 30–80
By country, each count listing its studies:
Carbidopa: first FDA approval 1975 (SINEMET), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 30 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 3 7 · Phase 4 9
First in 2004; this study’s year is marked. 3 started in 2005.
This study's enrollment of 359 is above the median of 40 across 3,357 interventional studies indexed under Parkinson Disease.
Median enrollment 46 across the 24 interventional studies. Of the 22 that completed or were terminated, 14 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 24 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
21 studies in Parkinson Disease by Novartis: none open now, none under way, none of them phase 3. Of 20 finished, 5 (25%) have results posted.
Among the 21 studies in Parkinson Disease by Novartis, this one is the 4th largest by enrollment, is one of 3 that started in 2005, is one of 6 in phase 4, and was the 2nd registered.
Novartis’s Parkinson Disease studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 24 studies testing carbidopa in Parkinson Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 21 in Parkinson Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To assess motor function and quality of life (QoL) in Parkinson's disease (PD) subjects with end-of-dose wearing off, comparing immediate and delayed switch to carbidopa/levodopa and entacapone.
This was a prospective, multi-center, randomized, open-label study with blinded raters to evaluate the effects of immediate versus delayed switch to carbidopa/levodopa/entacapone on motor function and quality of life in patients with Parkinson's disease with end-of-dose wearing off.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria applied to this study.
Patients were switched the day after randomization from combined carbidopa/levodopa to combined carbidopa/levodopa/entacapone. Patients received the same doses of carbidopa (12.5, 25.0, or 37.5 mg) and levodopa (50, 100, or 150 mg) they were receiving prior to the switch, combined with 200 mg of entacapone. The frequency of doses per day prior to the switch remained the same after the switch.
Drug: Carbidopa/levodopa/entacapone
Patients were switched 4 weeks after randomization from combined carbidopa/levodopa to combined carbidopa/levodopa/entacapone. Patients received the same doses of carbidopa (12.5, 25.0, or 37.5 mg) and levodopa (50, 100, or 150 mg) they were receiving prior to the switch, combined with 200 mg of entacapone. The frequency of doses per day prior to the switch remained the same after the switch.
Drug: Carbidopa/levodopa/entacapone
Drug pages: Carbidopa · Levodopa · Entacapone
Carbidopa/levodopa/entacapone was administered in 1 of 3 dose combinations: 12.5/50/200 mg, 25/100/200 mg, or 37.5/150/200 mg. The selected combination dose contained the same doses of carbidopa and levodopa the patient was receiving prior to switching to carbidopa/levodopa/entacapone.
Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score From Baseline to Week 4
Motor function was assessed with the UPDRS part III. There are 14 items in the instrument, each measured on a 5 point scale (0-4): Speech, facial expression, tremor at rest, action tremor, rigidity, finger taps, hand movements, hand pronation and supination, leg agility, arising from chair, posture, gait, postural stability, and body bradykinesia. The sum of scores can range from 0 to 56; a higher score indicates greater disability. A negative change score indicates improvement.
Time frame: Baseline to Week 4
Change in Parkinson's Disease Quality of Life Score From Baseline to Week 4
Quality of life was assessed with the Parkinson's Disease Quality of Life Instrument (PDQUALIF), a 33-item self-reported questionnaire which includes seven domains: Social/role function, self-imaging/sexuality, sleep, outlook, physical function, independence, and urinary function. Questions are scored on a 5-point Likert scale ranging from 1 (never) to 3 (sometimes) to 5 (always). The 1 to 5 range was recoded to 0 to 4 for the analysis. The total score can range from 0 to 132. A lower score indicates better quality of life. A negative change score indicates improvement.
Time frame: Baseline to Week 4
Change in Parkinson's Disease Quality of Life Score From Baseline to Week 8
Quality of life was assessed with the Parkinson's Disease Quality of Life Instrument (PDQUALIF), a 33-item self-reported questionnaire which includes seven domains: Social/role function, self-imaging/sexuality, sleep, outlook, physical function, independence, and urinary function. Questions are scored on a 5-point Likert scale ranging from 1 (never) to 3 (sometimes) to 5 (always). The 1 to 5 range was recoded to 0 to 4 for the analysis. The total score can range from 0 to 132. A lower score indicates better quality of life. A negative change score indicates improvement.
Time frame: Baseline to Week 8
Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score From Baseline to Week 8
Motor function was assessed with the UPDRS part III. There are 14 items in the instrument, each measured on a 5-point scale (0-4): Speech, facial expression, tremor at rest, action tremor, rigidity, finger taps, hand movements, hand pronation and supination, leg agility, arising from chair, posture, gait, postural stability, and body bradykinesia. The sum of scores can range from 0 to 56; a higher score indicates greater disability. A negative change score indicates improvement.
Time frame: Baseline to Week 8
Change in the 39-item Parkinson's Disease Questionnaire (PDQ-39) Total Score From Baseline to Week 4
The PDQ-39 is another instrument used to assess quality of life in individuals with Parkinson's disease. The questionnaire provides scores on eight scales: Mobility, activities of daily living, emotions, stigma, social support, cognition, communication, and bodily discomfort. Questions are scored on a 5-point Likert scale ranging from 1 (never) to 3 (sometimes) to 5 (always). The 1 to 5 range was recoded to 0 to 4 for the analysis. The total score can range from 0 to 156. A lower score indicates better quality of life. A negative change score indicates an improvement.
Time frame: Baseline to Week 4
Change in the 39-item Parkinson's Disease Questionnaire (PDQ-39) Total Score From Baseline to Week 8
The PDQ-39 is another instrument used to assess quality of life in individuals with Parkinson's disease. The questionnaire provides scores on eight scales: Mobility, activities of daily living, emotions, stigma, social support, cognition, communication, and bodily discomfort. Questions are scored on a 5-point Likert scale ranging from 1 (never) to 3 (sometimes) to 5 (always). The 1 to 5 range was recoded to 0 to 4 for the analysis. The total score can range from 0 to 156. A lower score indicates better quality of life. A negative change score indicates an improvement.
Time frame: Baseline to Week 8
Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score From Baseline to End of Treatment
Motor function was assessed with the UPDRS part III. There are 14 items in the instrument, each measured on a 5 point scale (0-4): Speech, facial expression, tremor at rest, action tremor, rigidity, finger taps, hand movements, hand pronation and supination, leg agility, arising from chair, posture, gait, postural stability, and body bradykinesia. The sum of scores can range from 0 to 56; a higher score indicates greater disability. A negative change score indicates improvement.
Time frame: Baseline to end of treatment (Week 16 in the Immediate Switch group, Week 20 in the Delayed Switch group)
Change in Parkinson's Disease Quality of Life Score From Baseline to End of Treatment
Quality of life was assessed with the Parkinson's Disease Quality of Life Instrument (PDQUALIF), a 33-item self-reported questionnaire which includes seven domains: Social/role function, self-imaging/sexuality, sleep, outlook, physical function, independence, and urinary function. Questions are scored on a 5-point Likert scale ranging from 1 (never) to 3 (sometimes) to 5 (always). The 1 to 5 range was recoded to 0 to 4 for the analysis. The total score can range from 0 to 132. A lower score indicates better quality of life. A negative change score indicates improvement.
Time frame: Baseline to end of treatment (Week 16 in the Immediate Switch group, Week 20 in the Delayed Switch group)
Change in the 39-item Parkinson's Disease Questionnaire (PDQ-39) Total Score From Baseline to End of Treatment
The PDQ-39 is another instrument used to assess quality of life in individuals with Parkinson's disease. The questionnaire provides scores on eight scales: Mobility, activities of daily living, emotions, stigma, social support, cognition, communication, and bodily discomfort. Questions are scored on a 5-point Likert scale ranging from 1 (never) to 3 (sometimes) to 5 (always). The 1 to 5 range was recoded to 0 to 4 for the analysis. The total score can range from 0 to 156. A lower score indicates better quality of life. A negative change score indicates an improvement.
Time frame: Baseline to end of treatment (Week 16 in the Immediate Switch group, Week 20 in the Delayed Switch group)
| Milestone | Immediate Switch | Delayed Switch |
|---|---|---|
| Started | 180 | 179 |
| Completed | 136 | 128 |
| Not completed | 44 | 51 |
| Withdrew: Adverse event | 26 | 24 |
| Withdrew: Abnormal laboratory value(s) | 0 | 1 |
| Withdrew: Lack of efficacy | 3 | 10 |
| Withdrew: Protocol violation | 9 | 5 |
| Withdrew: Withdrawal by subject | 5 | 9 |
| Withdrew: Lost to follow-up | 1 | 2 |
| Milestone | Immediate Switch | Delayed Switch |
|---|---|---|
| Started | 114 | 106 |
| Completed | 112 | 99 |
| Not completed | 2 | 7 |
| Withdrew: Adverse event | 2 | 3 |
| Withdrew: Withdrawal by subject | 0 | 2 |
| Withdrew: Lost to follow-up | 0 | 2 |
Motor function was assessed with the UPDRS part III. There are 14 items in the instrument, each measured on a 5 point scale (0-4): Speech, facial expression, tremor at rest, action tremor, rigidity, finger taps, hand movements, hand pronation and supination, leg agility, arising from chair, posture, gait, postural stability, and body bradykinesia. The sum of scores can range from 0 to 56; a higher score indicates greater disability. A negative change score indicates improvement.
| Units on a scale | Immediate Switch | Delayed Switch |
|---|---|---|
| Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score From Baseline to Week 4 | -3.7 ± 0.66 | -1.8 ± 0.58 |
Quality of life was assessed with the Parkinson's Disease Quality of Life Instrument (PDQUALIF), a 33-item self-reported questionnaire which includes seven domains: Social/role function, self-imaging/sexuality, sleep, outlook, physical function, independence, and urinary function. Questions are scored on a 5-point Likert scale ranging from 1 (never) to 3 (sometimes) to 5 (always). The 1 to 5 range was recoded to 0 to 4 for the analysis. The total score can range from 0 to 132. A lower score indicates better quality of life. A negative change score indicates improvement.
| Units on a scale | Immediate Switch | Delayed Switch |
|---|---|---|
| Change in Parkinson's Disease Quality of Life Score From Baseline to Week 4 | -0.4 ± 0.88 | 1.1 ± 0.77 |
Quality of life was assessed with the Parkinson's Disease Quality of Life Instrument (PDQUALIF), a 33-item self-reported questionnaire which includes seven domains: Social/role function, self-imaging/sexuality, sleep, outlook, physical function, independence, and urinary function. Questions are scored on a 5-point Likert scale ranging from 1 (never) to 3 (sometimes) to 5 (always). The 1 to 5 range was recoded to 0 to 4 for the analysis. The total score can range from 0 to 132. A lower score indicates better quality of life. A negative change score indicates improvement.
| Units on a scale | Immediate Switch | Delayed Switch |
|---|---|---|
| Change in Parkinson's Disease Quality of Life Score From Baseline to Week 8 | -2.5 ± 1.01 | -1.1 ± 0.89 |
Motor function was assessed with the UPDRS part III. There are 14 items in the instrument, each measured on a 5-point scale (0-4): Speech, facial expression, tremor at rest, action tremor, rigidity, finger taps, hand movements, hand pronation and supination, leg agility, arising from chair, posture, gait, postural stability, and body bradykinesia. The sum of scores can range from 0 to 56; a higher score indicates greater disability. A negative change score indicates improvement.
| Units on a scale | Immediate Switch | Delayed Switch |
|---|---|---|
| Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score From Baseline to Week 8 | -3.6 ± 0.71 | -3.7 ± 0.62 |
The PDQ-39 is another instrument used to assess quality of life in individuals with Parkinson's disease. The questionnaire provides scores on eight scales: Mobility, activities of daily living, emotions, stigma, social support, cognition, communication, and bodily discomfort. Questions are scored on a 5-point Likert scale ranging from 1 (never) to 3 (sometimes) to 5 (always). The 1 to 5 range was recoded to 0 to 4 for the analysis. The total score can range from 0 to 156. A lower score indicates better quality of life. A negative change score indicates an improvement.
| Units on a scale | Immediate Switch | Delayed Switch |
|---|---|---|
| Change in the 39-item Parkinson's Disease Questionnaire (PDQ-39) Total Score From Baseline to Week 4 | -1.7 ± 1.34 | 0.8 ± 1.17 |
The PDQ-39 is another instrument used to assess quality of life in individuals with Parkinson's disease. The questionnaire provides scores on eight scales: Mobility, activities of daily living, emotions, stigma, social support, cognition, communication, and bodily discomfort. Questions are scored on a 5-point Likert scale ranging from 1 (never) to 3 (sometimes) to 5 (always). The 1 to 5 range was recoded to 0 to 4 for the analysis. The total score can range from 0 to 156. A lower score indicates better quality of life. A negative change score indicates an improvement.
| Units on a scale | Immediate Switch | Delayed Switch |
|---|---|---|
| Change in the 39-item Parkinson's Disease Questionnaire (PDQ-39) Total Score From Baseline to Week 8 | -5.8 ± 1.48 | -1.9 ± 1.31 |
Motor function was assessed with the UPDRS part III. There are 14 items in the instrument, each measured on a 5 point scale (0-4): Speech, facial expression, tremor at rest, action tremor, rigidity, finger taps, hand movements, hand pronation and supination, leg agility, arising from chair, posture, gait, postural stability, and body bradykinesia. The sum of scores can range from 0 to 56; a higher score indicates greater disability. A negative change score indicates improvement.
| Units on a scale | Immediate Switch | Delayed Switch |
|---|---|---|
| Change in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score From Baseline to End of Treatment | -3.6 ± 0.69 | -3.3 ± 0.64 |
Quality of life was assessed with the Parkinson's Disease Quality of Life Instrument (PDQUALIF), a 33-item self-reported questionnaire which includes seven domains: Social/role function, self-imaging/sexuality, sleep, outlook, physical function, independence, and urinary function. Questions are scored on a 5-point Likert scale ranging from 1 (never) to 3 (sometimes) to 5 (always). The 1 to 5 range was recoded to 0 to 4 for the analysis. The total score can range from 0 to 132. A lower score indicates better quality of life. A negative change score indicates improvement.
| Units on a scale | Immediate Switch | Delayed Switch |
|---|---|---|
| Change in Parkinson's Disease Quality of Life Score From Baseline to End of Treatment | -1.3 ± 0.97 | 0.2 ± 0.89 |
The PDQ-39 is another instrument used to assess quality of life in individuals with Parkinson's disease. The questionnaire provides scores on eight scales: Mobility, activities of daily living, emotions, stigma, social support, cognition, communication, and bodily discomfort. Questions are scored on a 5-point Likert scale ranging from 1 (never) to 3 (sometimes) to 5 (always). The 1 to 5 range was recoded to 0 to 4 for the analysis. The total score can range from 0 to 156. A lower score indicates better quality of life. A negative change score indicates an improvement.
| Units on a scale | Immediate Switch | Delayed Switch |
|---|---|---|
| Change in the 39-item Parkinson's Disease Questionnaire (PDQ-39) Total Score From Baseline to End of Treatment | -2.8 ± 1.60 | 0.4 ± 1.47 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Immediate Switch | — | 8/180 (4.4%) | 100/180 (55.6%) |
| Delayed Switch | — | 12/179 (6.7%) | 66/179 (36.9%) |
| Event | Immediate Switch | Delayed Switch |
|---|---|---|
| Cardiac failure congestiveCardiac disorders | 0/180 | 2/179 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/180 | 2/179 |
| Atrial fibrillationCardiac disorders | 0/180 | 1/179 |
| Myocardial infarctionCardiac disorders | 0/180 | 1/179 |
| DiarrhoeaGastrointestinal disorders | 1/180 | 1/179 |
| Pancreatitis acuteGastrointestinal disorders | 0/180 | 1/179 |
| VomitingGastrointestinal disorders | 0/180 | 1/179 |
| AbscessInfections and infestations | 0/180 | 1/179 |
| BronchitisInfections and infestations | 0/180 | 1/179 |
| Viral infectionInfections and infestations | 0/180 | 1/179 |
| Event | Immediate Switch | Delayed Switch |
|---|---|---|
| NauseaGastrointestinal disorders | 31/180 | 13/179 |
| DiarrhoeaGastrointestinal disorders | 29/180 | 21/179 |
| DizzinessNervous system disorders | 16/180 | 13/179 |
| DyskinesiaNervous system disorders | 7/180 | 12/179 |
| FatigueGeneral disorders | 12/180 | 6/179 |
| ChromaturiaRenal and urinary disorders | 12/180 | 10/179 |
| ConstipationGastrointestinal disorders | 10/180 | 6/179 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 9/180 | 3/179 |
| TremorNervous system disorders | 9/180 | 6/179 |
| DepressionPsychiatric disorders | 9/180 | 7/179 |
| Age, Continuous(years) | Immediate Switch | Delayed Switch | Total |
|---|---|---|---|
| Mean | 68.7 ± 9.18 | 68.3 ± 10.38 | 68.5 ± 9.78 |
| Sex: Female, Male(Participants) | Immediate Switch | Delayed Switch | Total |
|---|---|---|---|
| Female | 74 | 71 | 145 |
| Male | 106 | 108 | 214 |
The record gives a start of Jan 2005, a primary completion of Jul 2008 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2011, 2 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Carbidopa · Levodopa · Entacapone